Cipcic-Bragadin Mesic & Associates has advised Pfizer on a global business combination with Mylan N.V. The transaction involved a spin-off of Pfizer’s Upjohn business and a subsequent merger of that business with Mylan N.V. to form a new global generics company, called "Viatris." Bird & Bird was global lead counsel to Pfizer, with Karanovic & Partners providing local support for Serbia and Jadek & Pensa providing local support in Slovenia.
According to Cipcic-Bragadin Mesic & Associates, “Viatris is forecast to have a market capitalization of about USD 24 billion and will include in its portfolio blockbuster products like Pfizer’s Viagra and Mylan’s EpiPen. It is now set to overtake the largest player in the global generics market, Teva, which commands more than USD 18.9 billion worth of global sales, according to European Pharmaceutical Review.”
Cipcic-Bragadin Mesic & Associates' team included Partners Silvije Cipcic-Bragadin and Marina Mesic.
Karanovic & Partners’ team included Senior Partner Marjan Poljak, Partner Milena Jaksic Papac, Senior Associates Ana Stankovic, Kevin Rihtar, and Boris Dvorscak, and Associate Milos Rubezic.
Jadek & Pensa's team included Managing Associate Iris Pensa, Senior Associate Nastja Merlak, and Senior Tax Manager Domen Romih.
Editor's Note: After this article was published Cobalt announced that it had provided Latvian law advice to Pfizer on the deal, and that the deal had closed on November 16, 2020. The firm's team included Partner Indrikis Liepa and Associates Janis Sarans and Ivo Maskalans.
Subsequently, on December 18, 2020, Clifford Chance Badea announced that it had advised Pfizer on Romanian aspects of the transaction. The firm's team included Partner Nadia Badea, Counsel Loredana Ralea, and Senior Associates Diana Crangasu and Andrei Caloian.